Analysis of the Efficacy of PD-1 Inhibitor Pembrolizumab Combined with Chemotherapy in the Treatment of Cervical Cancer
10.13241/j.cnki.pmb.2025.16.011
- VernacularTitle:PD-1抑制剂帕博利珠单抗联合化疗治疗宫颈癌效果分析
- Author:
GULBANU·MUHAIMAITI
1
;
ABIDAN·TURHAN
;
Li-li HAN
;
MAYINUER·NIYAZI
;
Dong-hui CAI
Author Information
1. 新疆医科大学研究生学院 新疆乌鲁木齐 830001
- Publication Type:Journal Article
- Keywords:
PD-1 inhibitor;
Pembrolizumab monoclonal antibody;
Chemotherapy;
Cervical cancer;
Security;
Survival period
- From:
Progress in Modern Biomedicine
2025;25(16):2651-2658
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy of the combination therapy of pembrolizumab,a programmed death receptor-1(PD-1)inhibitor,and chemotherapy in the treatment of cervical cancer.Methods:A total of 60 patients with cervical cancer who visited our hospital from January 2020 to January 2023 were selected and divided into two groups:30 patients were treated with first-line chemotherapy,and 30 patients were treated with pembrolizumab combined with first-line chemotherapy.Compare the recent efficacy of two groups,including immune related indicators[CD4+/CD8+ratio,interleukin-6(IL-6),interferon-γ(IFN-γ)],serum tumor markers[Squamous Cell Carcinoma Antigen(SCC Ag),Carbohydrate Antigen 125(CA125)],incidence of adverse reactions,and survival status[Progression Free Survival(PFS),Overall Survival(OS)]before and after treatment.Results:The objective response rate(ORR)of the combination group was 73.33％,while that of the chemotherapy group was 40.00％.The combination group was higher than the chemotherapy group(P＜0.05);There was no significant difference in the levels of CD4+/CD8+,IL-6,and IFN-γ between the two groups before treatment(P＞0.05).After treatment,the levels of CD4+/CD8+,IL-6,and IFN-γ decreased in the combination group,which was lower than those in the chemotherapy group(P＜0.05);There was no significant difference in the levels of SCC Ag and CA125 between the two groups before treatment(P＞0.05).After treatment,the levels of SCC Ag and CA125 in both groups decreased,with the combination group lower than the chemotherapy group(P＜0.05);There was no significant difference in the incidence of hematological toxicity(anemia,thrombocytopenia),immune related toxicity(hypothyroidism,immune pneumonia,elevated transaminase),skin/mucosal reactions(rash,oral mucosal inflammation),and other adverse reactions(diarrhea,fatigue)between the two groups(P＞0.05).The incidence of grade 3 or above neutropenia was higher in the chemotherapy group than in the combination group(P＜0.05);The PFS and OS time of the combined group were higher than those of the chemotherapy group(P＜0.05).Conclusion:The combination therapy of PD-1 inhibitor pembrolizumab and chemotherapy is significantly effective in treating cervical cancer,which can improve the immune environment,reduce serum marker levels,and has high safety.At the same time,through long-term follow-up,it was found that the combination therapy can further improve patients'long-term progression free survival and overall survival.
